The Wave

1. 6d agoSTATSTAT+: FDA warns GLP-1 drugs carry potential risk of rare eye conditionFDA ordered GLP-1 drug makers to add safety labeling warning patients and doctors of a potential risk of the rare eye condition NAION.

   2 articles

   1. 6d agoSTATEarliestSTAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition
   2. 5d agoSTATSTAT+: GLP-1s are given an FDA warning for rare eye condition risk

   Biotech9 linked
2. 6d agoYahooUS FDA orders new eye risk warnings for Ozempic, ZepboundThe FDA ordered GLP-1 weight-loss and diabetes drugs such as Zepbound, Mounjaro, Ozempic and Wegovy to add a potential eye-risk warning (NAION) to their labeling.1 outletBiotech6 linked
3. 6d agoYahoo · research by Food and Drug AdministrationFDA warns against online weight-loss drugs containing uncertain ingredientsFDA issued a warning letter to Cheap Medicine Shop and a safety alert on dosing errors, cautioning consumers about unapproved online semaglutide weight-loss injections.1 outletBiotech6 linked

Ahead

Nothing from this branch in view.

Times ET

Nothing in contracts is connected to this.